Stockreport

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Off...

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched tod [Read more]